NIMH Clinical Trial
NIMH AV-101 Phase 2 Monotherapy Study for MDD
The U.S. National Institute of Mental Health (NIMH), part of the U.S. National Institutes of Health (NIH), is currently evaluating AV-101 in a Phase 2 monotherapy study for the treatment of MDD. This study is being conducted by Dr. Carlos Zarate of the NIMH and fully funded by the NIMH.
Study Center and Contact
|National Institutes of Health Clinical Center
9000 Rockville Pike
Bethesda, MD 20892
|Carlos A Zarate, M.D.|
For more information about the study, please visit www.clinicaltrials.gov.